York Bioanalytical Solutions   Report issue

For profit Phase 1 Phase 3
Founded: York United Kingdom (1999)

Organization Overview

First Clinical Trial
2017
NCT03184987
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

York Bioanalytical Solution

Active Ingredients

Drugs in Phase 3 Trials (3)

fluticasone (cutivate) (1 trial)

umeclidinium (incruse ellipta) (1 trial)

vilanterol (Anoro Elipta) (1 trial)

Drugs in Phase 1 Trials (1)

gkt137831 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4